Nifty
:
25405.30
Sensex
:
83239.47
-48.10 (-0.19%)
-170.22 (-0.20%)
Nifty
Sensex
:
:
25405.30
83239.47
-48.10 (-0.19%)
-170.22 (-0.20%)

Lincoln Pharmaceuticals Ltd.

Pharmaceuticals & Drugs - Global

Rating :
53/99

BSE: 531633 | NSE: LINCOLN

NSE BSE
559.15
03-Jul-2025
  • Open
  • High
  • Low
  • Previous Close
  •  560
  •  564.95
  •  555.5
  •  558.65
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  36770
  •  20573866.95
  •  979.5
  •  499

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 1,118.96
  • 13.59
  • 10
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 1,096.53
  • 0.32%
  • 1.67

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 49.78%
  • 1.26%
  • 36.64%
  • FII
  • DII
  • Others
  • 5%
  • 0.00%
  • 7.32%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 8.11
  • 8.48
  • 7.13

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 14.59
  • 8.80
  • 0.91

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 20.05
  • 12.65
  • 10.39

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 10.51
  • 10.88
  • 12.98

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 1.68
  • 1.73
  • 1.87

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 7.32
  • 7.47
  • 8.30

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 25
Mar 24
Var%
Dec 24
Dec 23
Var%
Sep 24
Sep 23
Var%
Jun 24
Jun 23
Var%
Net Sales
168.18
142.49
18.03%
146.55
146.45
0.07%
161.21
155.99
3.35%
147.28
135.62
8.60%
Expenses
141.46
124.11
13.98%
122.89
116.79
5.22%
132.83
124.84
6.40%
124.55
114.90
8.40%
EBITDA
26.72
18.38
45.38%
23.66
29.66
-20.23%
28.38
31.15
-8.89%
22.73
20.72
9.70%
EBIDTM
15.89%
12.90%
16.15%
20.25%
17.60%
19.97%
15.43%
15.28%
Other Income
-6.88
7.02
-
8.97
11.02
-18.60%
9.98
8.70
14.71%
10.41
7.69
35.37%
Interest
0.37
0.50
-26.00%
0.73
0.16
356.25%
0.35
0.39
-10.26%
0.44
0.42
4.76%
Depreciation
3.23
2.69
20.07%
3.22
2.81
14.59%
3.22
2.58
24.81%
3.22
2.54
26.77%
PBT
16.25
22.22
-26.87%
28.68
37.71
-23.95%
34.78
36.87
-5.67%
29.48
25.45
15.83%
Tax
4.67
3.62
29.01%
7.91
9.67
-18.20%
8.45
9.21
-8.25%
5.81
6.43
-9.64%
PAT
11.57
18.60
-37.80%
20.77
28.04
-25.93%
26.33
27.65
-4.77%
23.67
19.01
24.51%
PATM
6.88%
13.05%
14.17%
19.15%
16.33%
17.73%
16.07%
14.02%
EPS
5.78
9.28
-37.72%
10.37
14.00
-25.93%
13.15
13.81
-4.78%
11.82
9.49
24.55%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Net Sales
623.22
580.55
510.31
472.12
424.19
386.49
366.15
360.61
360.26
400.15
266.07
Net Sales Growth
7.35%
13.76%
8.09%
11.30%
9.75%
5.56%
1.54%
0.10%
-9.97%
50.39%
 
Cost Of Goods Sold
291.31
204.07
179.43
169.71
155.86
138.15
135.66
156.44
202.90
254.64
161.12
Gross Profit
331.91
376.48
330.88
302.41
268.32
248.34
230.49
204.18
157.35
145.50
104.96
GP Margin
53.26%
64.85%
64.84%
64.05%
63.25%
64.26%
62.95%
56.62%
43.68%
36.36%
39.45%
Total Expenditure
521.73
480.64
421.11
376.64
337.01
320.95
298.91
308.30
313.52
359.62
240.47
Power & Fuel Cost
-
11.47
10.25
8.33
7.10
8.18
7.21
6.82
5.92
5.68
4.27
% Of Sales
-
1.98%
2.01%
1.76%
1.67%
2.12%
1.97%
1.89%
1.64%
1.42%
1.60%
Employee Cost
-
102.90
93.16
79.72
63.26
58.65
51.90
51.15
37.59
28.83
17.87
% Of Sales
-
17.72%
18.26%
16.89%
14.91%
15.18%
14.17%
14.18%
10.43%
7.20%
6.72%
Manufacturing Exp.
-
101.77
85.72
69.33
61.54
64.05
60.71
51.73
29.44
35.81
25.98
% Of Sales
-
17.53%
16.80%
14.68%
14.51%
16.57%
16.58%
14.35%
8.17%
8.95%
9.76%
General & Admin Exp.
-
30.49
31.06
27.56
23.06
21.30
20.98
17.50
14.78
20.34
18.86
% Of Sales
-
5.25%
6.09%
5.84%
5.44%
5.51%
5.73%
4.85%
4.10%
5.08%
7.09%
Selling & Distn. Exp.
-
26.71
19.20
19.49
24.54
26.79
20.02
21.24
19.91
10.10
9.42
% Of Sales
-
4.60%
3.76%
4.13%
5.79%
6.93%
5.47%
5.89%
5.53%
2.52%
3.54%
Miscellaneous Exp.
-
3.23
2.28
2.51
1.64
3.83
2.43
3.44
2.97
4.22
9.42
% Of Sales
-
0.56%
0.45%
0.53%
0.39%
0.99%
0.66%
0.95%
0.82%
1.05%
1.11%
EBITDA
101.49
99.91
89.20
95.48
87.18
65.54
67.24
52.31
46.74
40.53
25.60
EBITDA Margin
16.28%
17.21%
17.48%
20.22%
20.55%
16.96%
18.36%
14.51%
12.97%
10.13%
9.62%
Other Income
22.48
34.42
22.47
10.00
5.66
11.04
5.63
5.45
2.78
7.36
7.19
Interest
1.89
1.46
2.03
1.45
1.56
2.02
4.00
5.41
6.66
9.96
8.38
Depreciation
12.89
10.62
9.17
8.09
7.56
7.33
6.68
6.11
5.51
4.87
4.57
PBT
109.19
122.24
100.48
95.94
83.72
67.23
62.19
46.25
37.33
33.07
19.85
Tax
26.84
28.94
27.58
26.58
21.47
15.77
13.46
11.60
9.20
9.27
4.80
Tax Rate
24.58%
23.67%
27.45%
27.70%
25.65%
23.46%
21.64%
25.08%
24.65%
28.03%
24.18%
PAT
82.34
93.30
72.90
69.36
62.25
51.44
48.71
34.62
28.12
23.68
15.01
PAT before Minority Interest
82.34
93.30
72.90
69.36
62.25
51.47
48.74
34.65
28.13
23.80
15.04
Minority Interest
0.00
0.00
0.00
0.00
0.00
-0.03
-0.03
-0.03
-0.01
-0.12
-0.03
PAT Margin
13.21%
16.07%
14.29%
14.69%
14.68%
13.31%
13.30%
9.60%
7.81%
5.92%
5.64%
PAT Growth
-11.75%
27.98%
5.10%
11.42%
21.01%
5.60%
40.70%
23.12%
18.75%
57.76%
 
EPS
41.17
46.65
36.45
34.68
31.13
25.72
24.36
17.31
14.06
11.84
7.51

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Shareholder's Funds
592.84
502.47
432.88
366.39
313.09
269.34
224.22
192.38
140.52
111.31
Share Capital
20.03
20.03
20.03
20.03
20.00
20.00
20.00
20.00
16.31
16.31
Total Reserves
572.81
482.44
412.85
346.36
293.09
249.34
204.22
172.38
116.65
95.00
Non-Current Liabilities
15.18
38.02
10.99
26.10
42.85
28.43
24.94
31.75
33.74
33.14
Secured Loans
0.00
0.00
0.00
0.14
0.85
1.69
6.93
12.38
23.62
15.27
Unsecured Loans
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
10.21
Long Term Provisions
0.10
25.36
0.00
15.98
32.51
17.49
7.19
9.98
0.00
0.00
Current Liabilities
117.41
96.01
110.71
94.78
80.32
100.37
113.48
99.42
100.34
114.47
Trade Payables
72.44
50.87
71.67
57.07
51.24
44.01
43.42
32.46
30.38
45.31
Other Current Liabilities
15.18
14.51
9.84
13.43
9.13
11.11
11.11
12.77
15.10
11.52
Short Term Borrowings
1.07
2.00
2.04
0.00
3.83
30.09
48.55
45.04
52.62
50.67
Short Term Provisions
28.73
28.64
27.16
24.28
16.11
15.16
10.41
9.15
2.24
6.97
Total Liabilities
725.43
636.50
554.58
487.27
436.64
398.50
362.97
323.85
274.79
261.85
Net Block
179.33
150.53
131.88
110.64
122.72
120.91
116.58
102.71
98.47
65.62
Gross Block
236.65
197.47
171.07
141.90
146.70
138.11
127.65
108.16
120.89
87.50
Accumulated Depreciation
57.32
46.95
39.19
31.26
23.98
17.21
11.08
5.45
22.42
21.88
Non Current Assets
253.55
245.42
181.51
159.59
173.91
159.43
136.08
134.27
127.83
80.64
Capital Work in Progress
3.48
6.71
16.05
1.69
0.04
2.10
0.29
6.63
2.73
2.55
Non Current Investment
0.00
0.00
0.00
0.00
0.09
0.09
0.09
0.09
0.01
0.01
Long Term Loans & Adv.
70.74
88.18
31.83
46.81
51.02
36.01
18.79
24.48
26.62
12.47
Other Non Current Assets
0.00
0.00
1.75
0.45
0.03
0.33
0.34
0.36
0.00
0.00
Current Assets
471.87
391.08
373.07
327.69
262.73
239.08
226.88
189.58
146.98
181.20
Current Investments
138.92
91.33
96.81
80.66
34.22
18.07
10.97
10.25
0.00
0.00
Inventories
77.17
70.03
72.74
46.61
47.40
36.23
45.41
37.31
27.48
21.82
Sundry Debtors
161.77
136.33
115.94
113.35
101.34
122.47
109.44
90.67
80.53
119.01
Cash & Bank
13.83
34.32
18.80
13.84
14.58
7.58
14.59
11.68
12.66
11.51
Other Current Assets
80.19
2.10
1.19
1.43
65.20
54.74
46.47
39.68
26.31
28.86
Short Term Loans & Adv.
78.50
56.98
67.59
71.79
64.09
53.64
45.18
39.02
26.26
28.86
Net Current Assets
354.46
295.07
262.36
232.91
182.41
138.71
113.40
90.16
46.63
66.73
Total Assets
725.42
636.50
554.58
487.28
436.64
398.51
362.96
323.85
274.81
261.84

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Cash From Operating Activity
63.22
39.26
76.13
69.27
75.42
52.84
26.63
25.04
44.80
24.56
PBT
122.24
100.48
95.94
83.72
67.23
62.19
46.25
37.33
33.07
19.85
Adjustment
-16.76
-0.23
1.48
4.84
8.66
9.30
11.64
10.70
13.75
10.68
Changes in Working Capital
-16.12
-31.37
2.40
0.20
14.33
-1.12
-22.00
-13.24
4.80
-2.50
Cash after chg. in Working capital
89.37
68.87
99.83
88.76
90.22
70.38
35.88
34.79
51.62
28.02
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-26.15
-29.61
-23.70
-19.49
-14.81
-17.53
-9.25
-9.75
-6.82
-3.46
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-57.34
-36.64
-78.08
-64.23
-30.88
-18.19
-11.77
-25.48
-41.79
6.52
Net Fixed Assets
-35.95
-17.06
-43.53
-35.54
-5.59
-11.52
-12.45
4.05
-29.04
-4.21
Net Investments
-47.59
5.48
-16.15
-20.70
-14.20
-7.10
-2.72
-16.01
-7.34
-1.43
Others
26.20
-25.06
-18.40
-7.99
-11.09
0.43
3.40
-13.52
-5.41
12.16
Cash from Financing Activity
-5.18
-4.50
-2.56
-5.75
-37.76
-35.77
-11.41
0.30
-3.42
-32.04
Net Cash Inflow / Outflow
0.70
-1.88
-4.50
-0.70
6.77
-1.11
3.45
-0.14
-0.41
-0.96
Opening Cash & Equivalents
5.05
6.93
11.44
12.14
5.46
6.57
3.12
3.26
3.75
4.82
Closing Cash & Equivalent
5.75
5.05
6.93
11.44
12.23
5.46
6.57
3.12
3.43
3.87

Financial Ratios

Consolidated /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Book Value (Rs.)
295.98
250.86
216.12
182.92
156.54
134.67
112.11
96.19
81.52
68.24
ROA
13.70%
12.24%
13.31%
13.48%
12.33%
12.80%
10.09%
9.40%
8.87%
5.77%
ROE
17.04%
15.59%
17.35%
18.32%
17.67%
19.75%
16.63%
17.29%
19.49%
14.32%
ROCE
22.53%
21.82%
24.29%
24.90%
22.30%
22.50%
19.05%
18.51%
21.18%
15.91%
Fixed Asset Turnover
2.78
2.90
3.17
3.04
2.81
2.84
3.07
3.19
3.90
3.20
Receivable days
90.22
86.09
84.27
89.34
102.22
112.23
100.99
85.52
89.69
139.97
Inventory Days
44.55
48.72
43.86
39.12
38.19
39.51
41.74
32.36
22.16
30.72
Payable days
110.27
124.63
138.44
126.82
56.60
57.26
47.62
37.21
40.22
92.31
Cash Conversion Cycle
24.49
10.19
-10.30
1.64
83.82
94.48
95.11
80.67
71.63
78.37
Total Debt/Equity
0.00
0.00
0.00
0.00
0.02
0.12
0.27
0.34
0.59
0.69
Interest Cover
84.45
50.49
67.11
54.61
34.32
16.56
9.55
6.60
4.32
3.37

Annual Reports:

FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016
FY 2015

News Update:


  • Lincoln Pharmaceuticals completes trial run at new manufacturing facility in Gujarat
    2nd Jul 2025, 14:41 PM

    The facility is expected to commence the commercial production of APIs within 1 to 2 years

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.